SMARCB1 and carcinoma: In line with these findings, Glöss et al. recently reported a better disease-free survival for IDH2-mutant sinonasal carcinomas in comparison with SMARCB1 deficient carcinomas and IDH2 wild type carcinomas in a large series of sinonasal/skull base tumors [108].